GlaxoSmithKline Stock

GBP14.80

0.87%

London, Aug 22, 05:35 pm CET

ISIN

GB00BN7SWP63

Symbol

GSK

Index

FTSE 100, NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts Strategies

GlaxoSmithKline Stock price

GBP14.80

+2.54 20.76% 5Y

London, Closing price Fri, Aug 22 2025

-0.13 0.87%

ISIN

GB00BN7SWP63

Symbol

GSK

Index

FTSE 100, NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

GBP60.1b

Enterprise Value

GBP73.9b

Net debt

GBP13.7b

Cash

GBP3.6b

Shares outstanding

4.1b

Valuation (TTM | estimate)

P/E

17.8 | 8.9

P/S

1.9 | 1.8

EV/Sales

2.3 | 2.2

EV/FCF

15.8

P/B

4.1

Dividends

DPS

GBP0.61

Yield 1Y | 5Y

4.1% | 5.3%

Growth 1Y | 5Y

9.4% | -5.5%

Payout 1Y | 3Y

98.4% | 33.6%

Increased

1 Year

Financials (TTM | estimate)

Revenue

GBP31.6b | GBP33.2b

EBITDA

GBP8.1b | GBP11.3b

EBIT

GBP8.0b | GBP9.4b

Net Income

GBP3.4b | GBP6.9b

Free Cash Flow

GBP4.7b

Growth (TTM | estimate)

Revenue

0.6% | 5.7%

EBITDA

-1.9% | 37.4%

EBIT

-2.1% | 15.9%

Net Income

-15.1% | 168.9%

Free Cash Flow

-10.2%

Financial Health

Equity Ratio

23.0%

Return on Equity

18.8%

ROCE

20.5%

ROIC

18.5%

Debt/Equity

1.2

EPS

GBP0.8

FCF per Share

GBP1.1

Short interest

57.0%

Employees

69k

Rev per Employee

GBP460.0k

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

GlaxoSmithKline Stock Analysis

Unlock Scores for Free

??

30 Analysts have issued a GlaxoSmithKline forecast:

16x Hold

53%

10x Sell

33%

More details on Analyst Estimates Including Price Targets

30 Analysts have issued a GlaxoSmithKline forecast:

Buy

13%

Hold

53%

Sell

33%

Analyst Estimates with Stock Price Targets

Financial data from GlaxoSmithKline

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	31,631 31,631	1% 1% 100%
- Direct Costs	8,928 8,928	5% 5% 28%
Gross Profit	22,703 22,703	1% 1% 72%
- Selling and Administrative Expenses	8,925 8,925	1% 1% 28%
- Research and Development Expense	6,148 6,148	3% 3% 19%
EBITDA	8,056 8,056	2% 2% 25%
- Depreciation and Amortization	70 70	15% 15% 0%
EBIT (Operating Income) EBIT	7,986 7,986	2% 2% 25%
Net Profit	3,423 3,423	15% 15% 11%

In millions GBP.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Head office	United Kingdom
CEO	Emma Walmsley
Employees	68,629
Founded	1999
Website	www.gsk.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now